Omixon to Launch OmniType – Join Our Early Access Program!

21/10/2019

Omixon is gearing up to launch a Multiplex HLA typing product for use on Illumina sequencing platforms. This new product line – OmniType – is expected to be a best-in-class product featuring locus multiplexing and short library preparation. The requirements for its development came both from you in the...

A Letter from Omixon CEO, Dr. Peter Meintjes

30/01/2018

Dear Customers and Friends of Omixon, 2017 was one heck of a year – a year filled with growth and change; the year the Orville Omixon took flight to unchartered territories (and beyond?). Back in January 2017 we moved our company offices for the second time in our history,...

Holotype HLA Early Access Program Results: An “Uncontrolled” Study

26/05/2016

Authors: Efi Melista, Krisztina Rigó, Szilveszter Juhos, György Horváth, Peter Meintjes, Tim Hague Abstract: NGS-based (Next Generation Sequencing) HLA typing can offer accurate and unambiguous genotyping results with minimal manual intervention, eliminating the requirement for reflexive testing. In a clinical setting an easy-to-follow protocol with minimal hands-on time is also...

Holotype HLA Now CE-IVD in Europe

06/04/2016

Omixon announce today that Holotype HLA™ has been approved as a CE Marked IVD for sale in Europe, and will be available from April 2016 to all European customers as IVD, while remains RUO in the USA. Holotype HLA is the most globally recognized Next Generation Sequencing (NGS) Assay...

Omixon Holotype Early Access Program Featured at ASHI Annual Meeting 2015

23/09/2015

Omixon announce today that Holotype HLA™ and other Omixon products will be featured in four oral presentations and 12 poster presentations at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Savannah, Georgia. Additionally, in the Tuesday Vendor Symposium, Omixon’s CEO, Tim Hague, will present extended...